Australian biotech market today 15.04.09
Wednesday, 15 April, 2009
The healthcare index was a bright spot on an otherwise poor day for listed stocks, up 0.32 per cent at 3.30pm today.
Drug delivery company Acrux (ASX:ACR) is up 7c to 70c following yesterday’s ruling that it resume mediation with its US licensee, Vivus, over beginning a Phase III trial of its testosterone spray for women, Luramist.
Alchemia (ASX:ACL) was up 3.5c to 34c while Atcor (ASX:ACG) is up a cent to 21c on today’s news that it has signed two more sales contracts for its SphygmoCor blood pressure systems, bringing total contracts in the past year to US$7.3 million.
Circadian (ASX:CIR) was down a touch, while Cellestis (ASX:CST) lost some of yesterday’s gains, settling at $2.60.
Pharmaxis (ASX:PXS) has regained some of yesterday’s losses and is back over $2.00, while Mesoblast (ASX:MSB) is up a little.
Cochlear (ASX:COH) is down almost a dollar, while CSL (ASX:CSL) is up 40c and ResMed (ASX:RMD) is up 23c.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
